


Mesenchymal Stem Cells For

Degenerative Disc Disease

Patient Progression Report | November 25, 2021–December 31, 2022

Degenerative disc disease (DDD) is a condition that affects the discs between the vertebrae in the spine, which cause back pain and leg pain, as well as interferes with mobility. Between November 25, 2021 and December 31, 2022, a total of 181 patients have been treated at our clinic for this condition. This chart shows the age and gender of patients treated:




Oswestry Disability Index (ODI)

Patients were assessed three months and six months after therapy to evaluate treatment outcomes based on the Oswestry Disability Index—a widely used self-administered health status measurement scale for evaluating patients with DDD.

This questionnaire assesses how back or leg pain could affect the ability to manage activities in everyday life. With 10 questions, it quantifies disability related to low back pain and consists of 10 questions. Final scores range from 0 to 100 and are interpreted as shown here:

- **0–20 Minimal Disability**
- **21–40 Moderate Disability**
- **41– 60 Severe Disability**
- **61–80 Disabled**
- **81–100 Bedridden**

This chart compares ODI scores of patients before treatment, three months after treatment, and six months after treatment:



Of the 55 patients treated over a 6-month period, 46 (83.6%) responded after three months and 41 (75%) responded after six months.

Note that these patients provided their consent for follow-up using the InCytes web platform and to publish this clinical data. We plan to continue following up with patients and will issue updates when additional data becomes available.

Report By: BioXcellerator Science and Research Team